What is Amgen's kyprolis® (carfilzomib) — total revenues?

Amgen (AMGN) reported kyprolis® (carfilzomib) — total revenues of $359.00M in Q3 2025.

How has Amgen's kyprolis® (carfilzomib) — total revenues changed year-over-year?

Amgen's kyprolis® (carfilzomib) — total revenues decreased by 5.0% year-over-year, from $378.00M to $359.00M.

What is the long-term trend for Amgen's kyprolis® (carfilzomib) — total revenues?

Over 2 years (2022 to 2024), Amgen's kyprolis® (carfilzomib) — total revenues has grown at a 9.8% compound annual growth rate (CAGR), from $1.25B to $1.50B.

What does kyprolis® (carfilzomib) — total revenues mean?

The total revenue generated from the sales of the oncology drug Kyprolis.

Products & Services · Total revenues

KYPROLIS® (carfilzomib) — Total revenues

Amgen KYPROLIS® (carfilzomib) — Total revenues decreased by 5.0% to $359.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 5.0%, from $378.00M to $359.00M. Over 2 years (FY 2022 to FY 2024), KYPROLIS® (carfilzomib) — Total revenues shows an upward trend with a 9.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementSegment

CategoryGrowth

SignalHigher is better

VolatilityModerate

First reportedQ3 2020

Last reportedQ3 2025

Rolls up toTotal Revenue

How to read this metric

An increase indicates growing market share or successful clinical adoption in the multiple myeloma space, while a decrease may signal increased competition from generics, biosimilars, or newer therapeutic classes.

Detailed definition

This metric represents the total global net sales generated from the commercialization of the proteasome inhibitor thera...

Peer comparison

Comparable to revenue metrics for specialized oncology products or targeted therapies in the portfolios of large-cap biopharmaceutical peers.

Metric ID: amgn_segment_kyprolis_carfilzomib_total_revenues

Historical Data

17 periods

	Q2 '21	Q3 '21	Q1 '22	Q2 '22	Q3 '22	Q4 '22	Q1 '23	Q2 '23	Q3 '23	Q4 '23	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25
Value	$280.00M	$293.00M	$287.00M	$317.00M	$318.00M	$325.00M	$358.00M	$346.00M	$349.00M	$350.00M	$376.00M	$377.00M	$378.00M	$372.00M	$324.00M	$378.00M	$359.00M
QoQ Change	—	+4.6%	-2.0%	+10.5%	+0.3%	+2.2%	+10.2%	-3.4%	+0.9%	+0.3%	+7.4%	+0.3%	+0.3%	-1.6%	-12.9%	+16.7%	-5.0%
YoY Change	—	—	—	+13.2%	+8.5%	—	+24.7%	+9.1%	+9.7%	+7.7%	+5.0%	+9.0%	+8.3%	+6.3%	-13.8%	+0.3%	-5.0%

Range$280.00M – $378.00M

CAGR+6.4%

Avg YoY Growth+6.4%

Median YoY Growth+8.3%

Similar Metrics at Other Companies

Bristol-Myers SquibbBMY View metric

AbbVieABBV View metric

Johnson & JohnsonJNJ View metric

Frequently Asked Questions

What is Amgen's kyprolis® (carfilzomib) — total revenues?: Amgen (AMGN) reported kyprolis® (carfilzomib) — total revenues of $359.00M in Q3 2025.
How has Amgen's kyprolis® (carfilzomib) — total revenues changed year-over-year?: Amgen's kyprolis® (carfilzomib) — total revenues decreased by 5.0% year-over-year, from $378.00M to $359.00M.
What is the long-term trend for Amgen's kyprolis® (carfilzomib) — total revenues?: Over 2 years (2022 to 2024), Amgen's kyprolis® (carfilzomib) — total revenues has grown at a 9.8% compound annual growth rate (CAGR), from $1.25B to $1.50B.
What does kyprolis® (carfilzomib) — total revenues mean?: The total revenue generated from the sales of the oncology drug Kyprolis.